Amicus Ignite is a proactive community funding programme for initiatives that support people living with Pompe disease.
THE APPLICATION WINDOW IS NOW CLOSED

Through Amicus Ignite, we invite applications for initiatives that focus on:

01

Advances in Pompe management

02

Improvement of the Pompe patient care journey, from diagnosis through to care and disease management

We invite applications from across the Pompe community, including healthcare institutions, patient advocacy organisations, academic institutions and charitable organisations.

Funding of up to €20,000 (or local currency equivalent) for a limited number of projects is available. Projects need to be completed in one year and create lasting change for those impacted by Pompe disease.

Applications for projects that relate to a particular medicinal treatment or Amicus products are not permitted and will not be funded. Currently, applications are only open to organisations and projects located outside of the United States.

The application window is now closed.

The terms and conditions of the Amicus Ignite Funding Programme can be found here.

Meet the judges

Our panel of judges brings diverse experience to ensure fair and thoughtful selection.

Prof. Peter (Pitt) Young is the Clinical Director of Neurology at Medical Park, Bad Feilnbach Reithofpark, Germany. With expertise in neurophysiology, neurogenetics, intensive care and respiratory medicine, he has devoted his career to advancing care for neuromuscular and sleep-related disorders. Formerly leading key departments at the University of Münster, he is now medical director at Medical Park Bad Feilnbach. He serves as Past-President of the German Sleep Society and member of the scientific board of the German Muscle society representing the field of neurorehabilitation. His research continues to illuminate the complex interplay between sleep, genetics and neurological rehabilitation and health.

Prof. Peter (Pitt) Young

Medical Park, Bad Feilnbach Reithofpark

View Bio
Dr. Paul McIntosh is a Neuromuscular Neurologist at the University of Pennsylvania in Philadelphia. With training from the University of North Carolina, Duke, and Mass General Brigham, his clinical practice focuses on myopathies, in particular genetic myopathies. He brings a deeply personal perspective to patient care as someone living with Pompe disease. His diagnosis was his motivation to become a neuromuscular neurologist and continues to drive him to provide superb care and advocate for his patients. He has an interest in clinical research on Pompe disease and has a unique perspective being involved in clinical trials both as a patient and as an investigator. Throughout his career, he has published several articles on Pompe disease which have garnered over 50 citations, and he hopes to continue to contribute to the understanding of Pompe disease and improving patient care.

Dr. Paul McIntosh

University of Pennsylvania

View Bio
Tanya Collin-Histed is a Rare Disease Advocate and CEO of the International Gaucher Alliance (IGA), a role she has held since 2008. Her involvement in the rare disease community began when her daughter was diagnosed with Type 3 Gaucher disease, inspiring her support for patients and families worldwide. Tanya has led national and international organisations, campaigned for global access to treatment, and helped establish the GARDIAN registry for neuronopathic Gaucher disease.

Tanya Collin-Histed

International Gaucher Alliance

View Bio

Dr. Cristina Sancricca

Catholic University of Rome

View Bio
Steve Arnold is Chief, Global Head of Rare Disease at Amicus Therapeutics, bringing over 30 years of experience in the healthcare industry. He has led global teams in developing and delivering multiple therapies for rare conditions, including Pompe disease. His expertise in strategic planning and patient-focused innovation brings valuable insight to help advance therapies for people living with rare conditions.

Steve Arnold

Amicus Therapeutics

View Bio
Adam Jones is Vice President of International Medical at Amicus Therapeutics, where he oversees medical activities across ex-US affiliates and distributors. With over 25 years of experience in the pharmaceutical industry, he has led global clinical research and product launches across rare and infectious diseases, including Pompe disease. Adam has worked across the US, Europe, and Asia, and brings deep expertise to improve patient access to innovative therapies across the globe.

Adam Jones

Amicus Therapeutics

View Bio

Professor Peter (Pitt) Young is the Clinical Director of Neurology at Medical Park, Bad Feilnbach Reithofpark, Germany. With expertise in neurophysiology, neurogenetics, intensive care and respiratory medicine, he has devoted his career to advancing care for neuromuscular and sleep-related disorders. Formerly leading key departments at the University of Münster, he is now medical director at Medical Park Bad Feilnbach. He serves as Past-President of the German Sleep Society and member of the scientific board of the German Muscle society representing the field of neurorehabilitation. His research continues to illuminate the complex interplay between sleep, genetics and neurological rehabilitation and health. 

Dr. Paul McIntosh is a Neuromuscular Neurologist at the University of Pennsylvania in Philadelphia. With training from the University of North Carolina, Duke, and Mass General Brigham, his clinical practice focuses on myopathies, in particular genetic myopathies. He brings a deeply personal perspective to patient care as someone living with Pompe disease. His diagnosis was his motivation to become a neuromuscular neurologist and continues to drive him to provide superb care and advocate for his patients. He has an interest in clinical research on Pompe disease and has a unique perspective being involved in clinical trials both as a patient and as an investigator. Throughout his career, he has published several articles on Pompe disease which have garnered over 50 citations, and he hopes to continue to contribute to the understanding of Pompe disease and improving patient care. 

Tanya Collin-Histed is a Rare Disease Advocate and CEO of the International Gaucher Alliance (IGA), a role she has held since 2008. Her involvement in the rare disease community began when her daughter was diagnosed with Type 3 Gaucher disease, inspiring her support for patients and families worldwide. Tanya has led national and international organisations, campaigned for global access to treatment, and helped establish the GARDIAN registry for neuronopathic Gaucher disease.

Dr. Cristina Sancricca is a Neurologist and Clinical Researcher at the Catholic University of Rome, with a special focus on neuromuscular and metabolic disorders, including Pompe disease. She is an active contributor to international research on late-onset Pompe disease and is also involved in patient management and advocacy, being a member of the medical-scientific commission of the UILDM and medical director of the UILDM Lazio Foundation neurorehabilitation center. Through her clinical work and academic collaborations, Dr. Sancricca is dedicated to improving diagnosis, treatment, and quality of life for patients with rare neuromuscular conditions. 

Steve Arnold is Chief, Global Head of Rare Disease at Amicus Therapeutics, bringing over 30 years of experience in the healthcare industry. He has led global teams in developing and delivering multiple therapies for rare conditions, including Pompe disease. His expertise in strategic planning and patient-focused innovation brings valuable insight to help advance therapies for people living with rare conditions. 

Adam Jones (PhD)  is Vice President of International Medical at Amicus Therapeutics, where he oversees medical activities across ex-US affiliates and distributors. With over 25 years of experience in the pharmaceutical industry, he has led global clinical research and product launches across rare and infectious diseases, including Pompe disease. Adam has worked across the US, Europe, and Asia, and brings deep expertise to improve patient access to innovative therapies across the globe. 

Applications for 2025 are now closed. Amicus Ignite will relaunch in early 2026.

Apply now